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Summary
Cherubism is an autosomal dominant disorder that may
be related to tooth development and eruption. It is a
disorder of age-related bone remodeling, mostly limited
to the maxilla and the mandible, with loss of bone in
the jaws and its replacement with large amounts of fi-
brous tissue. We have used a genomewide search with
a three-generation family and have established linkage
to chromosome 4p16. Three other families affected with
cherubism were also genotyped and were mapped to the
same locus. The combined LOD score is 4.21 at a re-
combination fraction of 0, and the locus spans an in-
terval of ∼22 cM.
Introduction
Cherubism (CBM; MIM 11840) is characterized by a
loss of bone, restricted to the jaws, and by the replace-
ment of this bone with fibrous tissue. As first described
by Jones (1933), patients with CBM show symmetrical,
hard, and painless swelling of the jaws in childhood.
The involvement of the infraorbital rim and the orbital
floor leads to the upward tilting of the eyeballs and con-
sequent exposure of the inferior part of the sclerae. This
gives the child a cherubic” look, like that in Renaissance
portrayals of angels. Submandibular lymph-node en-
largement is often reported. In addition to the aesthetic
deformity and its psychological consequences, functional
impairment includes mastication and speech problems
(Faircloth et al. 1991), tooth alterations, and loss of
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normal vision (Marck and Kudryk 1992). The onset of
the disease is usually at 14 mo–4 years of age. It pro-
gresses through puberty, then stabilizes and, remarkably,
in some cases regresses without treatment (Katz et al.
1992; Timosca 1996).
The characteristic radiographic findings in CBM are
well-defined multilocular areas of diminished density, of-
ten very extensive, with a few irregular bony septa. In
the adult, the multilocular rarefactions become replaced
by sclerosis, with progressive calcification (Cornelius
and McClendon 1969).
No studies of the cellular and molecular basis for
CBM are available. To understand the pathogenic mech-
anisms that are involved in the bone resorption and dep-
osition of fibrous tissue in the jaws, we selected a genetic
approach. As a basis for gene identification, we have
determined the chromosomal locus for the cherubism
gene. Here we describe clinical findings in a three-gen-
eration family affected with cherubism and in a ge-
nomewide search to find linkage. The linkage data were
confirmed in three other families.
Subjects and Methods
Families
During the past 2 years, we have encountered 15 pa-
tients (10 males and 5 females) from four families with
CBM. Families were referred by clinicians in Brazil and
Germany (families A and D—Instituto de Cirurgia Plas-
tica Craniofacial, SOBRAPAR, Brazil, Dr. CassioM. Ra-
poso do Amaral; family B—Universidade Federal do Rio
Grande do Sul, Brazil, Dr. Francisco M. Salzano; family
C—Universita¨t zu Berlin, Institut fu¨r Medizinische Ge-
netik, Dr. Hartmut Peters). The clinical investigators
were responsible for explaining the research to the fam-
ilies and obtaining their informed consent, in accordance
with their local institutional review boards. The study
was approved by the Harvard Medical School and the
Forsyth Dental Center review boards. Peripheral blood
samples (3–5 ml) were collected and shipped to Boston.
Figure 1 Pedigree of family A affected with CBM. Haplotypes for each family member are listed below the pedigrees. The most likely haplotypes for the linked allele are indicated as boxed
areas. The arrow indicates the proband II-22.
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Figure 2 Proband of family A
Figure 3 Multilocular radiolucencies observed on ortopantomograph of proband
Genotyping
DNAs were isolated from the blood samples (Pure-
gene; Gentra Systems) and polymorphic microsatel-
lite markers (short-sequence-repeat polymorphisms
[SSRPs]) were selected (Dib et al. 1996) and purchased
from Research Genetics. PCR amplification of genomic
DNA was performed in a 10-ml volume containing 10
ng of template DNA and 4 pmol of each primer. The
forward primers were end-labeled with g[33P]-ATP. Con-
ditions for PCR included an initial denaturation step at
95C for 4 min, followed by 29 cycles at 94C for 40
s, 56C for 50 s, 72C for 50 s, with a final extension
at 72C for 10 min. PCR products were denatured at
95C for 5 min in the presence of 40% formamide. Ali-
quots (2.5 ml) were separated on denaturing polyacryl-
amide gels; this was followed by autoradiography.
Linkage analysis
Pairwise linkage analysis between the disease locus
and each of the marker loci, was performed by the
MLINK program of the LINKAGE package (Lathrop et
al. 1985), under the assumptions of a disease-gene fre-
quency of 0.1%, equal allele frequency, full penetrance,
autosomal dominant inheritance, and equal recombi-
nation rates for males and females.
Histology
Samples of affected tissues were collected from the
proband and were fixed in 4% paraformaldehyde in PBS
for 24 h. The samples were washed and were immersed
in 20% sucrose/PBS and were shipped to Boston. De-
calcification was performed in 10% formic acid, which
was changed every other day for 2 wk, on a shaker. The
samples were dehydrated in two 30-min changes of 70%
ethanol, followed by one 30-min change each of 90%
and 95% ethanol. This was followed by three 30-min
changes of 100% ethanol. The tissue was then immersed
in three 30-min changes of xylene, followed by a 1:1
solution of xylene/wax, and was left overnight at 60C.
Subsequently, the tissue was immersed in three 1-h
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Figure 4 Photomicrograph showing presence of multiple osteoclast-like cells within both cellular and fibrous tissue and bone fragment,
in biopsy of maxilla of proband (II-22) of family A (#100).
changes of paraffin at 60C, followed by embedding in
paraffin. Sections (7 mm) were made and were stained
with hematoxylin and eosin, weremounted in Permount,
and were analyzed by light microscopy.
Results
Clinical Findings
The evaluation of the proband (patient II-22) led us
to a three-generation family (family A), with eight af-
fected individuals—four males and four females (fig.
1)—displaying the CBM phenotype. Individuals within
the family were considered affected with CBM when
they presented clinical history of enlargement of maxilla
and/or mandible, with onset in childhood and/or radi-
ographic evidence of multilocular radiolucencies in the
jaws.
The proband, patient II-22 (fig. 2) is a 14-year-old
female with maxillary enlargement that started at age 5
years and has that has continued to date. The palatal
vault is obliterated because of bone overgrowth. Radi-
ographic multilocular radiolucencies (fig. 3), enlarged
submandibular lymph nodes, and numerous dental
anomalies were noted on both clinical and radiographic
examination. Histological analysis of lesion tissue
showed the presence of multiple osteoclast-like cells in
a fibrous and cellular stroma (fig. 4). Radiographs from
the whole body failed to show any other bone alteration.
A cytogenetic study did not show any chromosomal ab-
normalities. Both analysis of blood cells, proteins, and
ions (including parathyroid hormone, calcitonin, and
calcium) and coagulation tests failed to identify any ab-
normalities. Analysis of urinary constituents was also
normal. These findings are all consistent with the di-
agnosis of cherubism.
For family A, the mandible in males was more severely
affected than the maxilla, whereas in females the maxilla
was more severely affected. On average, the clinical on-
set of the disease was earlier in females (5.5 years of
age) than in males (10.6 years of age) (table 1).
Assignment of the CBM Gene to Chromosome 4p
We have mapped the locus for CBMbymeans of DNA
from family A (fig. 1). Traditional linkage analysis (Mor-
ton 1955; Dracopoli 1995) was first used to exclude
several potential candidate gene loci. After excluding
candidate-gene regions on chromosomes 6, 7, 9, 11, 12,
18, and 20, we switched to random mapping of the
entire genome, using a set of 360 polymorphic micro-
satellite markers (Dib et al. 1996) separated by an av-
erage distance of 10 cM.
Under the assumption of full penetrance, simulation
showed a maximum LOD score of 3.31 (recombination
fraction [v] 0). The haplotype analysis showed no re-
combination on chromosome 4p, for markers D4S1614,
D4S432, D4S3023, D4S2935, D4S3007, D4S394,
D4S3009, D4S1582, and D4S2928. Maximum LOD
scores (Zmax) were obtained for markers D4S1614,
D4S432, and D4S2928 ( ).Z  3.31max
By the same approach and methods, three other fam-
ilies (families B–D) were also analyzed. Haplotypes for
the three families showed no conflict with the data for
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Table 1
Presentation of the Disorder in the Affected Members of Family A
PATIENT SEX AGE AT EXAM (YEARS)
ENLARGEMENT
RADIOGRAPHIC
EVIDENCE
AGE AT ONSET (YEARS)Mandible Maxilla Mandible Maxilla
II-22 Female 14   Yes Yes 5
II-13 Female 31   Yes Yes 6
II-101 Female 8   Yes Yes 6
II-102 Female 9   Yes Yes 5
I-1 Male 56  * ) Yes No 12
I-20 Male 24  * ) Yes Yes 6
II-21 Male 23  ** ) Yes Yes 14
II-12 Male 32 ) ) Yes Yes )
* Asymmetry of the mandible, because of previous surgery.
** Asymmetry of the mandible, because of enlargement only of the left side.
Mild enlargement; moderate enlargement; severe enlargement; very severe enlargement.
family A, and the LOD scores were positive for all of
them. The combined LOD score for pedigrees A–D is
4.21 ( ) (table 2). The locus spans an interval ofv  0
∼22 cM, according to the Ge´ne´thon human linkage map
(Dib et al. 1996).
Family B (fig. 5) has been described elsewhere (Salzano
and Ebling 1966) and is composed of five members in
two generations. Both affected individuals are males.
The disease in this family shows linkage to the locus
established in family A, with no recombination for sev-
eral markers between D4S2957 and D4S2949. Z max
( ) for markers D4S1582, D4S394, and0.60 v  0
D4S2949.
Family C (fig. 5) consists of five members in three
generations, including three affected males. The disease
in this family shows linkage to chromosome 4, with
( ) for markers D4S394, D4S2935,Z  0.30 v  0max
D4S1582, and D4S2949.
Family D (fig. 5) consists of four members in two
generations, including one affected male and one af-
fected female. The disease in this family shows linkage
to the same locus on chromosome 4, with Z max
( ) for markers D4S3038, D4S1614, D4S432,0.30 v  0
and D4S394.
Discussion
Linkage of the cherubism locus was assigned to chro-
mosome 4p16 on the basis of data from family A. Hap-
lotype-analysis data from families B–D are supportive
of this linkage, although by themselves the LOD scores
for these families (0.60, 0.30, and 0.30 respectively)
would not be sufficient for assignment of linkage.
Affected members of the four families included in this
study show, in most cases, the typical characteristics of
CBM. However, our observations differ from previous
reports with regard to sex differences in expressivity and
to penetrance of the disorder. Variable expressivity is
reported for CBM, with 100% penetrance in males and
reduced penetrance in females—50%–70%—(Anderson
and McClendon 1962). In family A, however, reduced
penetrance in females was not observed. In fact, the
males of this family had a milder expression of the dis-
ease than was seen in the females. One of the affected
males (II-12) was diagnosed as affected on the basis of
radiographic evidence only, and he had no physical signs
of the disease.
For family A, the linkage data suggest that the locus
spans the interval between markers D4S2936 and
D4S2949. A critical individual in this family is the child
III-105. At this time, she is 2.5 years old, with no clinical
signs of the disease. Her radiographs show some dental
abnormalities that may not be related to the disease,
since her unaffected mother also presented with some
dental anomalies. Another clinical finding in this child,
however, was a preauricular appendage, a feature pre-
sent in her 23-year-old affected uncle, family member II-
21. The presence of a preauricular appendage has not
been previously reported as a characteristic feature of
CBM, but we cannot exclude the possibility that it is
associated with CBM in this family. The child III-105
shows a breakpoint between markers D4S2936 and
D4S1614. If we assume that she is not affected, then the
locus is defined as being between markers D4S2936 and
D4S2949. Recombinations in families B and D restrict
the locus further, to an interval of ∼21 cM between
markers D4S2936 and D4S1582. Should future analyses
indicate that subject III-105 is affected, the locus for the
CBM gene would be on the telomeric side of D4S2936.
At present, however, the most reasonable conclusion
from the linkage data on all four families is that the
locus for CBM is located on the telomeric side of
D4S1582. A total of 1.65 Mb from 4p16 has been se-
quenced in the course of identification of the Huntington
disease gene (Zuo et al. 1993). Many disorders—such
as achondroplasia (MIM 100800; Shiang et al. 1994;
Table 2
LOD Scores between CBM Locus and Chromosome 4p Markers
LOD SCORES AT v  0
LOCUS AND FAMILY 0 0.01 0.05 0.1 0.2 Zmax vmax
D4S3038:
A  .96 1.48 1.55 1.34 1.55 .1
B .81 .72 .50 .33 .15 .15 .2
C ) ) ) ) ) ) )
D .3 .29 .25 .21 .13 .3 0
D4S2936:
A  1.26 1.76 1.80 1.54 1.80 .07
B  1.34 .67 .40 .16 .16 .2
C 0 0 0 0 0 0 0
D ) ) ) ) ) ) )
D4S1614:
A 3.31 3.25 3.04 2.76 2.14 3.31 0
B ) ) ) ) ) ) )
C 0 0 0 0 0 0 0
D .3 .29 .25 .21 .13 .3 0
D4S432:
A 3.31 3.25 3.04 2.76 2.14 3.31 0
B .30 .29 .25 .21 .13 .3 0
C 0 0 0 0 0 0 0
D .30 .29 .25 .21 .13 .3 0
D4S3023:
A 1.20 1.18 1.11 1.02 .81 1.20 0
B .81 .72 .50 .33 .15 .15 .2
C 0 0 0 0 0 0 0
D 0 0 0 0 0 0 0
D4S2935:
A .60 .59 .55 .51 .40 .60 0
B .56 .55 .48 .40 .23 .56 0
C .30 .29 .27 .25 .20 .30 0
D 0 0 0 0 0 0 0
D4S3007:
A 2.70 2.66 2.48 2.25 1.74 2.70 0
B .54 .50 .37 .26 .12 .12 .2
C 0 0 0 0 0 0 0
D 0 0 0 0 0 0 0
D4S394:
A .60 .59 .55 .51 .40 .60 0
B .60 .58 .51 .42 .25 .60 0
C .30 .29 .27 .25 .20 .30 0
D .30 .29 .25 .21 .13 .30 0
D4S3009:
A 3.01 2.96 2.76 2.50 1.94 3.01 0
B .54 .50 .37 .26 .12 .12 .2
C 0 0 0 0 0 0 0
D 0 0 0 0 0 0 0
D4S1582:
A 1.20 1.17 1.05 .89 .57 1.20 0
B .60 .58 .51 .42 .25 .60 0
C .30 .29 .27 .25 .20 .30 0
D  1.4 .72 .44 .19 .19 .2
D4S2928:
A 3.31 3.25 3.04 2.76 2.14 3.31 0
B .30 .29 .25 .21 .13 .30 0
C 0 0 0 0 0 0 0
D 0 0 0 0 0 0 0
D4S2949:
A  .66 1.20 1.29 1.13 1.29 .1
B .60 .58 .51 .42 .25 .60 0
C .30 .29 .27 .25 .20 .30 0
D  1.4 .72 .44 —.19 —.19 .2
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Figure 5 Pedigrees of families B (A), C (B), and D (C) affected
with CBM. Haplotypes for each available family member are listed
below the pedigree. Boxed areas indicate the most likely alleles.
Rousseau et al. 1994), hypochondroplasia (MIM
146000; Bellus et al. 1995; Stoilov et al. 1995) andCrou-
zon syndrome (MIM 123500) with acanthosis nigricans
(Meyers et al. 1995)—are all caused by mutations in the
FGFR3 gene that map to chromosome 4p16. Both con-
genital stationary type 3 nightblindness (Gal et al. 1994)
and a subset of recessive retinitis pigmentosa (Mc-
Laughin et al. 1993) are caused by mutations in PDE6B
(MIM 180072), the most telomeric gene described on
chromosome 4.
According to Jones (1965), typical cases of cherubism
do not involve bones other than the maxilla and man-
dible. A few reports describe signs in other bones, such
as rarefaction or cystlike changes in the ribs (Wayman
1978) and the humerus (Thompson 1962). In the fam-
ilies described here, however, we did not find any evi-
dence of other bones being affected. Radiographic exams
of the whole body were performed for the proband of
family A, and no alterations were detected in other
bones. We conclude, therefore, that CBM in the families
that we studied is a localized disorder restricted to the
jaws. Considering that the bones of the jaws house the
developing teeth, one interesting possibility is that the
disorder may be related to the development of the per-
manent dentition (Jones 1965).
In patients with CBM, teeth may be displaced, une-
rupted, unformed, or absent or may appear to be floating
in cystlike spaces. Malocclusion, premature exfoliation
of deciduous teeth, and root resorption have also been
reported (McClendon et al. 1962). The disease does not
seem to be an early developmental disorder, since chil-
dren are born with no signs of the disease and usually
do not express any symptoms until several years after
birth. The disease develops in a time frame coinciding
with many different events of tooth development, par-
ticularly the eruption of the permanent dentition, and
the most dramatic expression of the disorder is seen at
age 5–15 years. Therefore, the tooth abnormalities may
indeed be related to the genetic causes of cherubism. In
family A, agenesis of teeth was present in two severely
affected females.
CBM has been reported in association withmosaicism
for both expansion and deletion of the FMR1 gene, with
clinical symptoms of mental retardation, prominent
forehead, and macroorchidism (Quan et al. 1995). As-
sociation of CBM with Noonan syndrome has also been
reported (MIM 163955; Dunlap et al. 1989). But finding
the locus for CBM on chromosome 4 confirms a sug-
gestion by Cohen and Gorlin (1991) that these disorders
are indeed different entities, since Noonan syndrome has
been mapped to chromosome 12 (Jamieson et al. 1994).
CBM, in association with gingival fibromatosis, has been
given the designation “Ramon syndrome” (MIM
266270; Ramon et al. 1967). One family has been de-
scribed with Ramon syndrome and juvenile rheumatoid
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arthritis (de Pina-Neto et al. 1986, 1998). Ramon syn-
drome has not yet been mapped, and it will be interesting
to test for linkage to the CBM locus.
Bone homeostasis reflects the balance between bone
formation by osteoblasts and bone resorption by oste-
oclasts. In CBM there is excessive bone resorption re-
stricted to the maxilla and mandible. Physical contact
with osteoblasts or marrow stromal cells is required for
osteoclast differentiation, and recent findings have led
to the identification of what are likely to be themolecular
mediators of this contact-dependent process. RANK, a
cell-surface receptor on osteoclast-progenitor cells (An-
derson et al. 1997), interacts with RANKL/TRANCE,
which appears to be identical to an osteoblast/stromal
cell–associated factor called “osteoclast differentiation
factor” (ODF) (Wong et al. 1997; Yasuda et al. 1998).
A soluble factor called “osteoclastogenesis-inhibitory
factor” (OCIF), with homology to osteoprotegerin
(OPG), can block the interaction between RANK and
RANKL, thereby inhibiting osteoclast differentiation (Si-
monet et al. 1997). In CBM, localized down-regulation
of a factor such as OPG could account for the increase
in osteoclast differentiation and could cause excessive
bone resorption in the maxilla and mandible.
The mutation causing CBM could be a factor involved
in the regulation of any of the genes regulating bone
formation or resorption, including CBFA1 (Mundlos et
al. 1997), RANK (Anderson et al. 1997), RANKL/
TRANCE/ODF (Wong et al. 1997; Yasuda et al. 1998)
and OPG/OCIF (Simonet et al. 1997). However, none
of these genes implicated in osteoblast and osteoclast
differentiation/function are mapped to chromosome 4p.
It is likely, therefore, that identifying the gene for CBM
will provide novel insights into bone homeostasis. It may
also have therapeutic consequences. At present there is
no rational treatment for CBM. In severe cases, when
there is functional and aesthetic impairment, surgical
intervention is necessary (Kaugars et al. 1992). Thus,
identification of the CBM gene not only should contrib-
ute significantly to the understanding of bone resorption
and formation in the mandible and maxilla but may also
help in the design of an effective therapy.
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